JB

Jillian R. Brown

BP Biomarin Pharmaceutical: 12 patents #10 of 139Top 8%
📍 Poway, CA: #120 of 1,186 inventorsTop 15%
🗺 California: #40,325 of 386,348 inventorsTop 15%
Overall (All Time): #319,461 of 4,157,543Top 8%
15
Patents All Time

Issued Patents All Time

Showing 1–15 of 15 patents

Patent #TitleCo-InventorsDate
10793894 Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2020-10-06
10683530 Detection of oligosaccharides Brett E. Crawford, Charles A. Glass 2020-06-16
10677786 Methods of diagnosing mucopolysaccharidosis (MPS) I and methods of monitoring treatment of MPS by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2020-06-09
10260084 Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2019-04-16
9915649 Methods of determining the presence, identity, and/or severity of mucopolysaccharidosis (MPS) VI and IVA Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2018-03-13
9796999 Detection of oligosaccharides Brett E. Crawford, Charles A. Glass 2017-10-24
9677116 Quantification of non-reducing end glycan residual compounds for determining the presence, identity, or severity of a disease or condition Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2017-06-13
9340822 Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2016-05-17
9029530 Detection of oligosaccharides Brett E. Crawford, Charles A. Glass 2015-05-12
8809009 Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2014-08-19
8771974 Methods of determining the presence and/or amount of a biomarker to determine the presence, identity, and/or severity of a lysosomal storage or neurological disorder Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2014-07-08
8725591 Method of reusing advertising material 2014-05-13
8592140 Detection of oligosaccharides Brett E. Crawford, Charles A. Glass 2013-11-26
8232073 Quantification of non-reducing end glycan residual compounds Brett E. Crawford, Charles A. Glass, Jim R. Beitel, Robin M. Jackman 2012-07-31
8183003 Polymer end group detection Brett E. Crawford, Charles A. Glass 2012-05-22